Sihuan pharm (00460.HK) announced that its non-wholly owned subsidiary, Huisheng Bio, has reached an exclusive licensing cooperation with Meiyan Space regarding the semaglutide injection developed by Huisheng Bio for the treatment of overweight or obesity indications.

The semaglutide developed by Huisheng Bio is a long-acting GLP-1 receptor agonist that promotes insulin secretion, suppresses glucagon secretion, delays gastric emptying, increases satiety, and reduces appetite and food intake by activating GLP-1 receptors. This product has been approved for clinical trials in the mainland china for weight loss indications, and the phase III clinical enrollment for type 2 diabetes indications has been completed.